Q515 - Notice of Intent to Sole-Source Requirement: Artera AI Prostate Exam Testing - Cleveland VAMC
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
250-NETWORK CONTRACT OFFICE 10 (36C250)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36C25027Q0088
NAICS
541380 - Testing Laboratories and Services
Classification Code
Q515
Additional Details
The Department of Veterans Affairs, Network Contracting Office (NCO) 10, has issued a Special Notice (Procurement Identifier: 36C25027Q0088) indicating its intent to award a sole-source contract for Artera AI Prostate Exam Testing at the Cleveland VA Medical Center, part of the VA Northeast Ohio Healthcare System (VANEOHS). This procurement is governed by the authority of FAR 6.302-1, which allows for sole-source awards when only one responsible source can meet the agency’s requirements.
The primary purpose of this contract is to provide access to specialized multi-modal artificial intelligence (MMAI) prostate risk stratification testing. This advanced testing is designed to analyze prostate biopsies or surgical specimens, integrating H&E-stained pathology slides with patient clinical data (such as age, tumor stage, and laboratory results) to assess the likelihood and severity of prostate cancer recurrence or progression. The Artera AI platform utilizes predictive modeling to determine which patients may benefit from specific therapies, including short-term androgen deprivation therapy (ST-ADT), and estimates long-term outcomes such as disease progression and metastasis risk. These insights are intended to support clinicians in tailoring treatment plans, enabling early intervention and improving patient outcomes for prostate cancer patients.
Artera AI Prostate is notable for being the first MMAI test recommended in the NCCN Clinical Practice Guidelines for prostate cancer. Its capabilities include identifying patients who may benefit most from hormone therapy and supporting early-stage treatment decisions, thereby providing actionable information to guide therapy selection.
The contract will be awarded to Artera, Inc. (UEI: S8PHW2AWT2R7), as it is believed to be the only provider capable of meeting the VA’s requirements for this specialized testing. The associated NAICS code is 541380 (Testing Laboratories and Services), with a size standard of $19 million. The Product Service Code is Q515. There are no set-aside requirements for this procurement, and it is not a solicitation or request for offers; no solicitation package is available. The place of performance is Ohio, United States.
Interested parties who believe they can meet the requirements are invited to submit a capability statement, proposal, or quotation for consideration. Responses must demonstrate clear and convincing evidence of the ability to comply with the requirement and show that competition would be advantageous to the Government. All responses should be emailed to Thomas Bellamy ([email protected]) and Samantha Jarrett ([email protected]) by 3:00 p.m. EST on November 10, 2026. The Government will not pay for information submitted, and the determination to compete or not is at the sole discretion of the Government.
The contracting entity is the 250-Network Contract Office 10 (36C250), a federal office within the Department of Veterans Affairs. For further information, contractors may refer to the official notice on SAM.gov (Opportunity ID: 3a45ee3ebd004e03ac5f852d0bfd4a67).
This opportunity is best suited for organizations with proven expertise in advanced AI-driven pathology testing and risk stratification for prostate cancer, particularly those familiar with MMAI platforms and clinical integration in oncology settings. The requirements and objectives outlined in this notice will remain constant throughout the contract lifecycle, focusing on precision medicine and improved patient outcomes for veterans.